Stock Movers: Intel, ServiceNow, West Pharma (Podcast)

Intel delivered a blockbuster sales forecast that beat Wall Street expectations and sent shares up 20% in extended trading to record territory, supported by AI-driven demand. ServiceNow plunged after results disappointed investors and management cited delayed Middle East deals tied to the ongoing conflict, while West Pharma rose on an earnings beat and raised full-year adjusted EPS guidance.

Analysis

The biggest second-order read-through is not just that AI demand is real, but that the supply chain is still under-allocated to a small set of compute enablers. A sharp rerating in the laggard foundry/CPU complex can pull capital and attention away from the obvious beneficiaries, but it also raises the bar for peers: if Intel can print a materially better guide, investors will demand faster capacity monetization and clearer AI attach rates across the semiconductor stack over the next 1-2 quarters.

The software disappointment looks more like a timing shock than a structural demand break, but the market is likely to treat any geopolitically linked delay as a proxy for broader enterprise procurement fragility. That matters because large-ticket workflow and transformation deals are usually booked late in the quarter; even a modest slippage can compress near-term ARR visibility and force multiple compression across high-multiple enterprise software names for 30-90 days, especially where expectations were already demanding.

West Pharma is the cleaner fundamental signal: if packaging inputs are seeing better-than-expected pass-through and guide raises, that suggests pharma manufacturing demand is holding up while cost discipline remains intact. The market may be underestimating how quickly that can ripple to adjacent life-science tools and consumables, which tend to re-rate on incremental evidence of stable biologics capex and higher utilization rather than headline growth alone.

The contrarian read is that the Intel move could be partially momentum-chasing: after a strong year-to-date run, the stock now needs proof that this guide translates into sustained margin expansion, not just a temporary inventory/capex cycle lift. Conversely, the software selloff may overshoot if the delay is truly region-specific; the best asymmetric setup may be to fade indiscriminate weakness in high-quality enterprise software once the market separates execution risk from one-off geopolitical friction.

Key Decisions for Investors

• Initiate a tactical long INTC on strength only if post-earnings volume confirms institutional accumulation; target a 4-8 week trade, but keep size modest because after a large guide-driven gap the next leg depends on margin credibility, not just sales momentum.
• Use NOW weakness to build a staggered long over 1-3 weeks if the selloff drags the multiple below the peer group on unchanged FY outlook; risk/reward improves if the market is pricing a demand shock from what appears to be a timing issue.
• Pair trade: long WST / short a basket of slower-growing life-science tools peers for a 1-2 quarter horizon; the setup is best if investors begin rewarding earnings revisions over end-market beta.
• Hedge enterprise software exposure with a short basket in the highest-duration workflow names into the next month; if deal delays are contagious, multiple compression can outlast the headline earnings miss.
• Avoid chasing INTC upside after the open; consider call spreads instead of outright equity for a 1-2 month bullish expression to cap risk if the market starts discounting a post-earnings mean reversion.